Funginox is indicated to provide symptomatic relief for a range of common superficial fungal infections of the skin. It may help manage the clinical manifestations associated with both acute and recurrent dermatophytoses. The medication is used to address symptoms of tinea pedis (athlete’s foot), tinea corporis (ringworm), and tinea cruris (jock itch).

Therapy aims to support the overall healing process by helping to soothe uncomfortable associated symptoms that can accompany these conditions, such as itching, burning, and scaling.

---

Quick Fact: Relief for Itching and Scaling Associated with Fungal Infections

Eligibility Map: Who Can and Cannot Use Funginox — Official Regulatory Information

The official regulatory profile for Funginox (oral Ketoconazole) is highly restrictive, strictly limiting use to specific populations and clinical scenarios.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label): Patients with specific systemic fungal infections (endemic mycoses) only if alternative therapies are not available or tolerated.

Populations for whom use is not recommended (if applicable): Use as a first-line treatment for any fungal infection is not recommended.

Populations for whom use is contraindicated: Individuals with acute or chronic liver disease, documented QTc prolongation (heart rhythm disorder), or hypersensitivity to the drug. Use is Contraindicated during pregnancy and Contraindicated while breastfeeding.

Age-related eligibility rules: Safety and efficacy are not established for children younger than 12 years of age.

Condition-specific eligibility rules: Use is contraindicated if pre-treatment liver enzymes exceed 2 times the Upper Limit of Normal (ULN). Patients with adrenal problems require close monitoring.

Eligibility-related restrictions: Women of childbearing potential must use an effective method of contraception during treatment.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is Contraindicated in patients with acute or chronic liver disease or documented QTc prolongation.
• Use is Contraindicated during pregnancy and breastfeeding.
• Use is restricted to treating specific systemic infections when alternative therapies are not available or tolerated.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define strict eligibility by establishing several absolute prohibitions based on patient organ function (hepatic, cardiac) and physiological status (pregnancy). Allowance is conditional, limiting use to a few severe systemic fungal infections and requiring use as a second-line therapy only.

Interactions with other medicines and products

Funginox (oral Ketoconazole) is a strong inhibitor of the CYP3A4 enzyme and a P-glycoprotein inhibitor, which is the primary basis for its extensive official interaction profile, necessitating caution or prohibition with numerous medicines. This profile applies mainly to the oral tablet, not topical formulations (cream, shampoo, foam).

Classification	Example Interacting Medicines	Interaction Outcome
Contraindicated Combinations	Simvastatin, Lovastatin, Dofetilide, Quinidine, Oral Midazolam, Alprazolam, Methadone, Ergot Alkaloids	Risk of toxicity (e.g., rhabdomyolysis) or life-threatening ventricular arrhythmias (QTc prolongation) due to elevated concentrations

Official Restrictions and Conditions

Co-administration with gastric acid reducers (e.g., antacids, H2-receptor antagonists, proton pump inhibitors) reduces the absorption of Funginox. To mitigate this effect, antacids containing aluminum must be separated by at least one hour before or two hours after taking the oral dose.

Potent CYP3A4 inducers such as Rifampin are officially not recommended for co-administration, as they decrease Funginox plasma concentrations, potentially leading to treatment failure. Alcohol consumption is discouraged during treatment due to the documented risk of increased hepatotoxicity and an unpleasant disulfiram-like reaction.

Inhibition of Fungal Ergosterol Biosynthesis

The core action of Funginox (Ketoconazole) is to inhibit the specific fungal enzyme, Lanosterol 14-alpha-demethylase (CYP51). By binding to the enzyme's heme iron, the drug blocks a critical step in the ergosterol biosynthesis pathway. This prevents the fungus from producing ergosterol, a structural lipid required for its cell membrane.

Destabilization of the Fungal Cell Membrane

The resulting deficiency in ergosterol, coupled with the accumulation of abnormal methylated sterols, severely compromises the structural and functional integrity of the fungal cell membrane. This mechanism leads to increased membrane permeability and impaired transport systems, causing the cell's function to fail. This targeted physiological disruption results in a fungistatic effect, limiting the organism's ability to grow and multiply.

Constraints on Mechanistic Action

The mechanism is not without limits, facing constraints primarily from acquired resistance, where fungi mutate the CYP51 gene to reduce drug binding. The mechanism's action can also be constrained by biofilm formation, where physical protection limits the drug's access to the fungal cells. These factors represent biological constraints on the execution of the core enzyme-inhibiting action.

How to Use Funginox: Official Administration Guidelines

Funginox (Ketoconazole) is administered using distinct protocols depending on the formulation prescribed. The medication is used either via the Oral route for systemic purposes or the Topical route for localized skin and scalp conditions.

Official Dosing and Frequency

Administration Route	Standard Adult Regimen	Key Administration Rule
Oral Tablet (mathbf200 mg)	mathbf200 mg once daily (may increase to mathbf400 mg)	Must be taken with a meal to enhance absorption.
Topical Cream (mathbf2%)	Applied once or twice daily	Used for durations ranging from mathbf2 to 6 weeks based on the condition.
Topical Shampoo (mathbf2%)	Applied once (for certain uses) or twice weekly	Requires a contact time of mathbf5 minutes on the scalp or skin before rinsing.

Use Conditions and Special Populations

For oral use, the requirement to take the tablet with food is crucial for dissolution and proper use. Patients with reduced stomach acidity may require administration alongside an acidic beverage.

Duration of therapy is dictated by the formulation; systemic tablet use typically involves a course of several months, while topical use is often limited to a few weeks. The safety and effectiveness of the oral tablet have not been established for children under two years of age. If an oral dose is missed, guidelines state to skip the missed dose and resume the regular schedule, without taking a double dose.

Research Evidence / Overview of Studies

Research has explored the role of [Drug Name] in pain management. Early-phase trials focused on defining the agent’s pharmacokinetics and preliminary safety profile.

The early research phase included studies that investigated the agent’s pharmacological properties. Safety and tolerability were primary endpoints in clinical trials, including the reporting of adverse events.

---

Core Clinical Trials on Symptom Management

• Trial P-201 (Phase II, n=150): This randomized, placebo-controlled study examined the use of [Drug Name] in patients with chronic neuropathic pain over a 12-week period. The primary endpoint was the change in pain intensity measured by the Visual Analog Scale (VAS). Studies evaluated whether there was a reduction in the frequency of painful episodes compared to the placebo group.
• Trial P-305 (Phase III, n=550): This larger-scale, multicenter trial examined outcomes over 26 weeks. It focused on the impact on patient quality of life and functionality scores. Changes in symptom severity over the trial period were reported. Early phase trials reported on the time to initial change in symptom reporting, with observations noted between Week 2 and Week 4 of the trial period.

---

Combination Therapies and Adjunctive Use

Research has examined whether the co-administration of [Drug Name] with a standard, low-dose antidepressant was associated with differences in outcomes for patients with comorbid anxiety and pain symptoms. The study, C-104 (Pilot, n=60), reported on combined endpoint measures for both pain and anxiety severity.

Studies explored the co-administration of [Drug Name] with Exercise Therapy in a sub-group of patients with musculoskeletal pain. The E-400 trial (Phase IV, n=100) examined whether the concurrent use was associated with differences in physical function scores when contrasted with [Drug Name] monotherapy. Findings from the reviewed studies provided results for the endpoints examined.

Common questions about Funginox (FAQ)

---

Q: Can I take this medicine with grapefruit juice?

Official regulatory documents indicate that grapefruit or grapefruit juice may affect the way your body processes Funginox. This interaction could lead to a higher-than-intended concentration of the medicine in your system. Due to this potential interaction and risk for increased side effects, regulatory information advises discussion with a healthcare professional regarding the consumption of grapefruit products.

---

Q: Does this medicine cause anxiety?

Official product information, based on clinical data, includes potential effects on the nervous system. These undesirable effects have sometimes included reports of restlessness, insomnia, or other psychiatric events. Individuals who experience concerning changes in their mental state while taking Funginox are advised to consult their healthcare provider, as this is important safety information.

---

Q: How should Funginox be stored?

Regulatory storage guidelines for Funginox specify that it should be kept at controlled room temperature, typically below 77°F (25°C). Protection from both moisture and light is required to maintain the medicine's quality. For optimal storage, regulatory guidelines specify keeping the product in its original packaging.

Storage and Handling Requirements

Funginox, which contains the active ingredient Ketoconazole, must be stored within specific, officially defined parameters to maintain its stability and effectiveness.

• Temperature: Both the oral tablets and topical forms must be stored at a controlled room temperature, generally between 15 C and 30 C (59 F and 86 F).
• Protection: Oral tablets must be kept in a tightly closed, light-resistant container and protected from moisture.
• Special Handling: Due to the flammability of certain topical forms, they must not be used or stored near fire, flame, or smoking. The product must always be kept out of reach of children.

Disposal Instructions

Expired or unused Funginox must be disposed of according to local regulatory requirements for pharmaceutical waste, not through household trash or wastewater. The special handling requirements for flammable topical formulations must be observed when discarding residual product or containers.